Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis

NCT01433497 is registered in ClinicalTrials.gov with AB Science as lead sponsor.

NCT NCT01433497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01433497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Lead sponsor
AB Science
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2011
Completion date
February 29, 2020
Enrollment
656 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, primary progressive, multiple sclerosis, relapse free, multiple sclerosis, secondary progressive